- Home
- ADGM vs PRPO Comparison
ADGM vs PRPO Comparison
Compare ADGM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- PRPO
- Stock Information
- Founded
- ADGM 2011
- PRPO N/A
- Country
- ADGM United States
- PRPO United States
- Employees
- ADGM N/A
- PRPO N/A
- Industry
- ADGM
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ADGM
- PRPO Industrials
- Exchange
- ADGM NYSE
- PRPO Nasdaq
- Market Cap
- ADGM 19.7M
- PRPO 17.1M
- IPO Year
- ADGM N/A
- PRPO N/A
- Fundamental
- Price
- ADGM $1.38
- PRPO $14.51
- Analyst Decision
- ADGM
- PRPO
- Analyst Count
- ADGM 0
- PRPO 0
- Target Price
- ADGM N/A
- PRPO N/A
- AVG Volume (30 Days)
- ADGM 44.3K
- PRPO 20.2K
- Earning Date
- ADGM 08-25-2025
- PRPO 08-12-2025
- Dividend Yield
- ADGM N/A
- PRPO N/A
- EPS Growth
- ADGM N/A
- PRPO N/A
- EPS
- ADGM N/A
- PRPO N/A
- Revenue
- ADGM $576,000.00
- PRPO $20,029,000.00
- Revenue This Year
- ADGM N/A
- PRPO N/A
- Revenue Next Year
- ADGM N/A
- PRPO N/A
- P/E Ratio
- ADGM N/A
- PRPO N/A
- Revenue Growth
- ADGM 116.54
- PRPO 26.67
- 52 Week Low
- ADGM $0.63
- PRPO $3.90
- 52 Week High
- ADGM $9.34
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- PRPO 63.53
- Support Level
- ADGM N/A
- PRPO $13.83
- Resistance Level
- ADGM N/A
- PRPO $15.47
- Average True Range (ATR)
- ADGM 0.00
- PRPO 1.18
- MACD
- ADGM 0.00
- PRPO -0.01
- Stochastic Oscillator
- ADGM 0.00
- PRPO 62.16
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.